Cipla's Revenue Growth Defies Market Challenges Despite Profit Drop

Cipla Ltd, a leading drugmaker, reported a significant drop in net profit for the March quarter, plummeting by 55.32% to Rs 542.51 crore due to slumping revenues in North America and increased expenditures.

The company has, however, achieved its highest-ever annual revenue, indicative of a resilient core business. Notably, its 'One India' sales increased by 15% compared to the same period last year, highlighting Cipla's robust domestic market strategy.

Despite challenges, Cipla plans to grow key markets, enhance flagship brands, and prioritize regulatory resolutions. The board recommended a final dividend for shareholders, showcasing confidence in its ongoing financial strategy.

(With inputs from agencies.)